Particularly, the emergence of Programmed cell Death-1 (PD-1) and Programmed cell Death-Ligand 1 (PD-L1) inhibitors has brought breakthrough treatment progress for patients with advanced NSCLC, increasing the five-year survival rate from 4.9% to 16%, significantly improving the prognosis of patients (5). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.